Pediatric Rheumatology, University of Alabama Birmingham, Birmingham, AL, United States.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, United States.
Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119. eCollection 2019.
Synonymous with secondary hemophagocytic lymphohistiocytosis, macrophage activation syndrome (MAS) is a term used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE). Clinical and laboratory features of MAS include sustained fever, hyperferritinemia, pancytopenia, fibrinolytic coagulopathy, and liver dysfunction. Soluble interleukin-2 receptor alpha chain (sCD25) and sCD163 may be elevated, and histopathology often reveals characteristic increased hemophagocytic activity in the bone marrow (and other tissues), with positive CD163 (histiocyte) staining. A common hypothesis as to the pathophysiology of many cases of MAS proposes a defect in lymphocyte cytolytic activity. Specific heterozygous gene mutations in familial HLH-associated cytolytic pathway genes (e.g., ) have been linked to a substantial subset of MAS patients. In addition, the pro-inflammatory cytokine environment, particularly IL-6, has been shown to decrease NK cell cytolytic function. The inability of NK cells and cytolytic CD8 T cells to lyse infected and otherwise activated antigen presenting cells results in prolonged cell-to-cell (innate and adaptive immune cells) interactions and amplification of a pro-inflammatory cytokine cascade. The cytokine storm results in activation of macrophages, causing hemophagocytosis, as well as contributing to multi-organ dysfunction. In addition to macrophages, dendritic cells likely play a critical role in antigen presentation to cytolytic lymphocytes, as well as contributing to cytokine expression. Several cytokines, including tumor necrosis factor, interferon-gamma, and numerous interleukins (i.e., IL-1, IL-6, IL-18, IL-33), have been implicated in the cytokine cascade. In addition to broadly immunosuppressive therapies, novel cytokine targeted treatments are being explored to dampen the overly active immune response that is responsible for much of the pathology seen in MAS.
与继发性噬血细胞性淋巴组织细胞增生症同义,巨噬细胞活化综合征(MAS)是风湿病学家用来描述系统性炎症性疾病的一种潜在危及生命的并发症的术语,最常见的是全身幼年特发性关节炎(sJIA)和系统性红斑狼疮(SLE)。MAS 的临床和实验室特征包括持续发热、高铁蛋白血症、全血细胞减少、纤维蛋白溶解性凝血障碍和肝功能障碍。可溶性白细胞介素 2 受体 alpha 链(sCD25)和 sCD163 可能升高,组织病理学通常显示骨髓(和其他组织)中特征性的噬血细胞活性增加,CD163(组织细胞)染色阳性。许多 MAS 病例的病理生理学的一个常见假设是淋巴细胞细胞溶解活性缺陷。家族性 HLH 相关细胞溶解途径基因(如)的特定杂合基因突变与相当一部分 MAS 患者有关。此外,促炎细胞因子环境,特别是 IL-6,已被证明会降低 NK 细胞的细胞溶解功能。NK 细胞和细胞溶解 CD8 T 细胞不能裂解感染和其他激活的抗原呈递细胞,导致细胞间(固有和适应性免疫细胞)相互作用延长,并放大促炎细胞因子级联反应。细胞因子风暴导致巨噬细胞活化,引起噬血作用,并导致多器官功能障碍。除了巨噬细胞外,树突状细胞可能在抗原呈递给细胞溶解淋巴细胞方面发挥关键作用,并有助于细胞因子表达。几种细胞因子,包括肿瘤坏死因子、干扰素-γ 和许多白细胞介素(即 IL-1、IL-6、IL-18、IL-33),已被牵连到细胞因子级联反应中。除了广泛的免疫抑制疗法外,还正在探索新型细胞因子靶向治疗方法,以抑制负责 MAS 中大部分病理的过度活跃免疫反应。